(Q43726109)

26 November 2017

Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions (English)

1 reference

Cysticercosis Working Group in Peru

26 November 2017

1 reference

1 reference

6

object named as

Cysticercosis Working Group in Peru

1 reference

26 November 2017

E J Pretell

1

1 reference

26 November 2017

H H García

2

1 reference

26 November 2017

R H Gilman

3

1 reference

26 November 2017

H Saavedra

4

1 reference

26 November 2017

M Martinez

5

1 reference

26 November 2017

1 October 2001

1 reference

Clinical Neurology and Neurosurgery

26 November 2017

1 reference

26 November 2017

103

1 reference

26 November 2017

3

1 reference

26 November 2017

175-177

1 reference

Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG)

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

1 reference

7 January 2021

Taenia solium cysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Albendazole therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Short course of albendazole therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Single-day praziquantel therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Treatment of porcine cysticercosis with oxfendazole: a dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Effective, single-dose treatment or porcine cysticercosis with oxfendazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Treatment of porcine cysticercosis with albendazole

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2801%2900137-8

7 January 2021

10.1016/S0303-8467(01)00137-8

Identifiers

DOI

1 reference

26 November 2017

1 reference